Brief: Metavia Inc - Announces Positive Ai-Modeling Results From Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets For Vanoglipel
04/02/2026 13:06
Feb 4 (Reuters) - SyntekaBio Inc 226330.KQ: METAVIA INC - ANNOUNCES POSITIVE AI-MODELING RESULTS FROM ONGOING SYNTEKABIO COLLABORATION, CONFIRMING KEY THERAPEUTIC TARGETS FOR VANOGLIPEL Source text: ID:nPn8G9Qy9a Further company coverage: 226330.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syntekabio
See all newsBrief: Metavia Inc - Announces Positive Ai-Modeling Results From Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets For Vanoglipel
Brief: Syntekabio Wins 397 Million Won Order
Brief: Syntekabio To Conduct Capital Increase Of 32 Billion Won
Brief: Metavia Announces Ai-Driven Collaboration With Syntekabio To Explore Additional Indications For Da-1241